Researchers identify a specific lipid metabolite that is abnormally abundant in IBD patients. Their subsequent investigations reveal how this metabolite stimulates the growth of species that are well established to be overrepresented in IBD patients.
Investigators expand on prior CMIT research to define
the chemical structure of two important glycosylation enzymes. By combining advanced cryo-electron
microscopy with traditional western blot analysis, scientists identify the subtle structural differences in
two related human oligosaccharyltransferase complexes that accounts for their unique cellular
In a recent study, researchers use single cell sequencing of intestinal tissue biopsies from diseased and healthy patients to create a cell atlas that lends novel insight into the cellular pathways that link implicated genes to UC pathophysiology.
To look for associations between the gut microbiome composition and development of Type 2 Diabetes, CMIT collaborated with researchers at institutes and hospitals within Mexico to study a cohort that had not been been diagnosed with, or treated for T2D, avoiding the potential influences of medication and lifestyle changes on gut microbes.
The Center for Microbiome Informatics and Therapeutics was founded to accelerate the development of therapeutics to treat microbiome-associated disease, with a core focus on Inflammatory Bowel Disease (IBD).
CMIT is collaborating with Dr. Patricia Pringle and Dr. Raymond Chung from Massachusetts General Hospital (MGH) on a new study that is investigating the potential role of fecal microbiota transplantation (FMT) as a treatment for hepatic encephalopathy.